SCYNEXIS, Inc.
First Candidate from SCYNEXIS’ Novel Cyclophilin Inhibitor Platform, SCY-635, Establishes Proof of Concept in HCV-Infected Adults
Published in Hepatitis Weekly, January 19th, 2009
Drug discovery company, SCYNEXIS, Inc., announced top-line results from a Phase 1b randomized, double-blind, placebo-controlled study of its lead oral antiviral drug candidate, SCY-635, in adult patients with chronic hepatitis C (HCV) infection. Treatment with SCY-635 was well tolerated and produced a clinically relevant reduction in plasma HCV RNA. Full results of the study will be presented in 2009. SCY-635, a cyclophilin inhibitor, represents a new class of drugs for the treatment of HCV infection and is the first candidate from a broad platform of proprietary cyclophilin inhibitors developed by SCYNEXIS.
“These data are very encouraging, demonstrating the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2009-01-19)
More Articles from Hepatitis Weekly
- World Journal of Gastroenterology
A new light on the anti-tumor mechanisms of Scutellaria barbata - Acute Hepatitis
New acute hepatitis study findings have been published by N. Walsh and colleagues - Hepatitis B Virus
New data from M.F. Han et al illuminate research in hepatitis B virus - Hepatitis B Virus
New hepatitis B virus study findings recently were reported by A. Alexopoulou and co-researchers - Hepatitis B Virus
Reports by A.Z. Zeng and co-researchers describe recent advances in hepatitis B virus - Hepatitis B Virus
Research from F. Suzuki and co-researchers in the area of hepatitis B virus described - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
